Sponsored by:
Breaking Boundaries in Drug Discovery: The Rise of Targeted Protein Degraders
Targeted protein degraders like PROTACs, LYTACs, AUTACs, and DACs are redefining modern therapeutics. These tools eliminate disease-causing proteins, even those once considered “undruggable”.They offer new hope for treating cancer, inflammation, and neurodegenerative disorders.
This white paper explores the science, progress, and potential of these powerful technologies. It also highlights the vital role of digital tools like Revvity Signals in streamlining collaboration and accelerating discovery.
Whether you're a researcher, biotech innovator, or healthcare leader, this resource offers essential insights into the next generation of drug design.
Download the White Paper to Learn About:
- Types of degraders: PROTACs, LYTACs, AUTACs, DACs
- Applications in cancer and neuro diseases
- AI and teamwork in R&D
- Design and delivery challenges
- Precision medicine impact
- Smarter data and workflow tools
